Side-by-side · Research reference
PEG-MGFvsTesamorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED2/69 cited
BFDA-ApprovedFlagship27/68 cited
PEG-MGF
IGF-1Ec Splice Variant · PEGylated
~2 hrHalf-life (PEG)
~7 minNative MGF t½
IGF-1EcSplice variant
SQ · Research Protocol
Tesamorelin
GHRH Analogue · FDA-Approved
SQ · Abdomen · Once Daily
01Mechanism of Action
Parameter
PEG-MGF
Tesamorelin
Primary target
IGF-1 receptor on muscle satellite cells and myocytes
Hypothalamic GHRH receptorsEGRIFTA® (tesamorelin for inje 2010
Pathway
IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion
GHRH → Pituitary GH release → Liver IGF-1 synthesisFalutz 2007
Downstream effect
Satellite cell activation, muscle fiber repair, localized hypertrophy signaling
Increased GH pulsatility, elevated IGF-1, lipolysis of visceral adipose tissueFalutz 2010
Feedback intact?
Partially bypassed — does not require hepatic IGF-1 synthesis
Yes — physiological pulsatility preserved
Origin
IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation
Synthetic 44-AA GHRH analogue with trans-3-hexenoic-acid modification for stabilityEGRIFTA® (tesamorelin for inje 2010
Antibody development
Unknown — no long-term human immunogenicity data
~50% after 26 wks (non-neutralising in most)Sévigny 2018
02Dosage Protocols
Parameter
PEG-MGF
Tesamorelin
Research dose range
100–200 mcg
Extrapolated from animal models; no validated human protocols.
—
Frequency
Post-training or daily
Timing to match endogenous MGF pulse post-exercise.
Once daily (morning or pre-sleep)
Aligns with natural GH pulse.
Half-life
~2 hours (PEGylated)
Native MGF: ~7 min; PEGylation extends circulation.
~26 min (plasma)EGRIFTA® (tesamorelin for inje 2010
Modified vs native GHRH (7 min t½).
Reconstitution
Sterile bacteriostatic water
Lyophilized form; store reconstituted at 2–8 °C.
Sterile water per labeling
Preserved at 2–8 °C after reconstitution.
PEG molecular weight
Typically 5–30 kDa
Higher MW = longer t½, greater steric hindrance.
—
Timing
Within 30–60 min post-training
Aligns with endogenous MGF window.
Empty stomach, pre-sleep preferred
Duration
—
12–52 weeks
VAT returns within months of stopping.
03Metabolic / Fat Loss Evidence
Parameter
PEG-MGF
Tesamorelin
Primary target
Muscle tissue (satellite cells, myocytes) — not adipose-specific
—
Indirect metabolic effect
IGF-1 signaling may modulate insulin sensitivity and lipid metabolismRen 2015
Mechanism distinct from direct lipolytic peptides.
—
Body composition
Lean mass preservation / hypertrophy focus
—
Fat loss evidence
No direct human or animal RCT data for PEG-MGF-driven fat reduction
—
Primary fat target
—
Visceral adipose tissue (VAT) — abdominal
Effect on lean mass
—
Modest lean mass preservation / slight increase
Effect reversibility
—
VAT returns within months of stopping
Key publication
—
Falutz et al. NEJM 2007 · Falutz JCEM 2010 · FDA approval 2010Falutz 2007Falutz 2010EGRIFTA® (tesamorelin for inje 2010
04Side Effects & Safety
Parameter
PEG-MGF
Tesamorelin
Injection site reaction
Erythema, induration (common with SQ peptides)
Erythema, pruritus, redness (common)
Hypoglycemia risk
IGF-1 axis activation can lower blood glucose
—
IGF-1R overstimulation
Theoretical risk of aberrant cell proliferation with chronic supraphysiological exposure
—
Fluid retention
Possible with IGF-1 pathway activation (dose-dependent)
—
PEG accumulation
Chronic high-dose PEGylated proteins may accumulate in tissues; clearance slower in renal impairment
—
Antibody formation
PEGylated proteins can elicit anti-PEG antibodies (neutralizing potential unknown)
~50% at 26 weeks; non-neutralising in most; rare hypersensitivity (<1%)Sévigny 2018
Cancer risk
IGF-1 axis stimulation contraindicated in active malignancy
Contraindicated in active malignancy (GH/IGF-1 axis); theoretical tumour growth riskEGRIFTA® (tesamorelin for inje 2010
Human safety data
Absent — no published human trials for PEG-MGF
—
Fluid retention / Edema
—
Peripheral edema, arthralgia, carpal tunnel (GH-axis effect)
IGF-1 elevation
—
Dose-dependent; supraphysiological levels = discontinue
GI symptoms
—
Nausea, diarrhea (mild, transient)
Absolute Contraindications
PEG-MGF
- ·Active malignancy or history of cancer (IGF-1R proliferative signaling)
- ·Known hypersensitivity to PEGylated compounds
- ·Pregnancy / lactation (no reproductive toxicity data)
Tesamorelin
- ·Active malignancy or history of treated cancer
- ·Pregnancy
- ·Hypersensitivity to tesamorelin or mannitol
- ·Disruption of hypothalamic-pituitary axis (trauma, tumour, radiation)
Relative Contraindications
PEG-MGF
- ·Diabetes (monitor glucose closely)
- ·Renal impairment (PEG clearance reduced)
- ·Retinopathy (IGF-1 axis effects on vascular proliferation)
Tesamorelin
- ·Untreated diabetes (monitor HbA1c)
- ·Severe carpal tunnel syndrome
- ·Acute critical illness
05Administration Protocol
Parameter
PEG-MGF
Tesamorelin
1. Reconstitution
Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.
Add 2.1 mL sterile water to 2 mg lyophilised vial. Roll gently — do not shake. Solution should be clear.
2. Injection site
Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.
Subcutaneous — abdomen preferred. Rotate sites (avoid same spot within 2 cm). Avoid navel and waistband area.
3. Timing
Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.
Once daily. Preferred: evening, 2–3 hrs post-meal, before sleep — aligns with natural GH secretion pulse.
4. Storage
Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 21 days.
5. Needle
29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.
27–31G, 4–8 mm insulin syringe. Pinch skin, 45° angle for lean individuals.
06Stack Synergy
PEG-MGF
+ BPC-157
ModerateBPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.
- PEG-MGF
- 100–200 mcg SQ post-training
- BPC-157
- 250–500 mcg SQ or oral, twice daily
- Duration
- 4–6 weeks (injury-dependent)
- Primary benefit
- Accelerated muscle and connective tissue repair, enhanced recovery
+ TB-500
StrongTB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.
- PEG-MGF
- 100–200 mcg SQ post-training
- TB-500
- 2–5 mg SQ, 2× per week (loading), then weekly
- Timing
- Stagger injections by 6–12 hours
- Primary benefit
- Maximal satellite cell recruitment and myogenic differentiation, injury repair
Tesamorelin
+ Ipamorelin
StrongTesamorelin (GHRH analogue) and ipamorelin (GHRP / ghrelin mimetic) act on two distinct receptor systems to amplify GH release synergistically — GHRH receptor + ghrelin receptor. This dual-axis stimulation produces a more robust, sustained GH pulse than either alone while maintaining physiological pulsatility. Ipamorelin is highly selective with minimal cortisol or prolactin elevation, making it the preferred GHRP pairing.
- Tesamorelin
- 2 mg SQ · evening
- Ipamorelin
- 200–300 mcg SQ · same injection
- Frequency
- Once daily, pre-sleep
- Primary benefit
- Maximal GH pulsatility, fat loss, recovery, sleep quality